HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife Executives' Investments Spark Uptick In Share Price After Results Send Stock Plummeting

Executive Summary

Since closing at a 14-year low of $8.07 the day of the execs’ transactions, Herbalife shares trend steadily up from close of $8.26 on 20 February to $8.83 on 29 February. Some execs sell back some shares on 25 February at $8.67.

You may also be interested in...

US Health And Wellness People News: CHPA Award, Herbalife, Mannatech C-Suite Changes, More

DeSimone returns as Herbalife CFO; Mannatech CEO Bala leaving on 1 April with Fredrick moving to post; CHPA lifetime achievement award for former Perrigo exec Needham; comedian hacks healthy nutrition for Quest; “John Wick” inspires Jacked; NBA player assists Earth Splendor; HRG owner group expands with HR director.

US Wellness Market People News: Herbalife, Bobbie Baby, Optimum Nutrition, Nutrabolt, More

“Gronk” motivates for Optimum Health; Osaka promotes paid paternal leave with Bobbie Baby; MidOcean changes CEOs at QualiTech; Nutrabolt expands revenue chief’s oversight; Gratziani climbs higher on Herbalife ladder; and Enzymedica adds Natural Group COO.

Hemp Regulation Flags Raised By States Wave Tougher Compliance Cloud Over Industry

Without FDA regulatory pathway for hemp’s lawful use in supplements and food, some states are imposing more-stringent regulations while others allow sales of intoxicating ingredients not considered controlled substances as hemp derivatives.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts